Posts Tagged ‘Pharmaceutical’

Quality Assurance Representative – North West

Thursday, February 2nd, 2012

Hannah Milward is currently recruiting for a Quality Assurance Representative to join a global manufacturer of pharmaceutical and veterinary medicine products based in the Merseyside region. They require a Contract Quality Assurance Representative to join their team for an initial period of 12 months.

Job Purpose:

The successful candidate for this Quality Assurance Representative will provide the Quality Assurance Team the assurance that manufacturing is carried out in accordance with cGMP and Regulatory commitments and that production records provide full and accurate documentation of batch manufacture in accordance with SOP. The QAR is authorised, as appropriate, by the QA Team Leader to disposition materials with consideration being given to the Regulatory requirement for QP release of veterinary and medicinal products. The job holder also exercises control on the general cGMP activities for those teams he/she has QA responsibility for.

Responsibilities:

The responsibilities of this Quality Assurance Representative role will include:

• Disposition raw materials, including packaging items, water, intermediates and products according to the available data, including evaluation of any deviation reports, environmental monitoring (where appropriate), and advise on reprocessing or preventive actions in such cases.

• Monitor trends and identify problems in quality of purchased materials, packaging, intermediates, products, water and environmental data and promote action having regard to changes in processes, facilities, equipment and procedures.

• Write/revise/approve and give advise on quality documentation e.g. batch production records, specifications, procedures (Team and Site), PMISsheets, Stability protocols.

• Review and approve SOPs (Team and Site), change control documentation, validation protocols, completed validation packages, IQ/OQ/PQ protocols.

• Manage the Site stability programme to meet Corporate and Regulatory requirements.

• To advise on the investigation of customer complaints, approve customer complaint reports and promote corrective/preventive actions

• Participate in self-inspections and other audits of the manufacturing and relevant Support areas with particular reference to cGMP as defined by the various regulatory authorities.

• Provide training, support, advice and proactive assistance in the Site Quality systems to the product and support teams.

• Advise on and support appropriate validation of plant, processes and new projects, liaising with other disciplines appropriately to ensure that facilities are designed and commissioned to meet cGMP.

• Provide cover for other QARs in their absence.

• Prepare Quality Agreements as appropriate.

• Liaise with Contract Manufacturers, as appropriate, to ensure that the Quality systems at the Contract Manufacturers comply with Corporate/Regulatory requirements and that the Quality systems are being implemented appropriately.

Qualifications and skills:

To be considered for this Quality Assurance Representative position you will have experience working in a similar role reviewing and supplying batch record documentation to the QP for release. You will also have experience working in the Pharmaceutical industry. 

How to apply:

For more information or to apply for this Quality Assurance Representative role please contact Hannah Milward on 0114 2839956 or email hmilward@ckscience.co.uk. Please quote reference SH23570 in all correspondence.

                                       Click here to search our jobs in science now!

Associate Director of GMP based in London

Wednesday, November 23rd, 2011

 

Jason Johal at CK Science is currently recruiting for an Associate Director for GMP to join a global pharmaceutical company based in London.

The role:

As Associate Director of GMP, you will be expected to provide regional strategic direction and oversight for GMP quality for all IMP developmental compounds, and commercial products for which the group is the marketing application holder.

You will also be expected to ensure alignment with global strategic objectives, and participate in the development and implementation of these from Phase 1 through to Phase 3 and 4, and commercial products.

The role also encompasses manufacture, testing, packaging and shipment to ensure compliance with regulatory requirements.

Day-to-day activities will include the management and overseeing of quality requirements of the IMP and MA supply chains (from API to labelled stock, release, importation and distribution) including all vendors, internal and external, ensuring appropriate management of quality compliance requirements including technical/quality agreements, audits, performance and compliance monitoring, feedback and improvements.

There will be the need to ensure that the regulatory release requirements are properly coordinated and that the QP network has available to it all relevant information for batch release and importation (API to study site or commercial distribution releases). There will also be the need to participate in Global Investigational Quality initiatives and regular activities, including meetings in order to assure that developmental GMP quality operations and compliance activities are aligned and compliant with applicable regulations.

The ideal candidate:

To be considered for this Associate Director role you will have extensive experience in commercial and drug development of pharmaceuticals in relevant functions of quality/production/other support functions along with experience in QA/QC in the pharmaceutical industry and managerial or senior level planning or project management experience in a relevant environment.

In addition, you will have specific experience in one or more of the following; IMPs, commercial product supply, clinical research is essential and experience across API, drug substance, drug product, packaging and labelling of pharmaceutical products, preferably in global and multi-disciplinary drug development/production environment is preferred. An understanding and working knowledge of Quality Management Systems with the ability to interpret requirements, anticipate issues, make informed decisions and respond rapidly to emerging quality situations is also essential. Though not essential QP status or training would be welcomed.

How to apply:

For more information or to apply for this Associate Director please contact Jason Johal at CK Science on 01438 723 500 or email jjohal@ckscience.co.uk. Please quote reference ST23186 in all correspondence.

Sales Consultant – Northern Scotland

Thursday, November 3rd, 2011

Carrie-Ann Bell is recruiting for a Sales Consultant to join a contract research organisation to the pharmaceutical, food, and agrochemical industries at their site in Northern Scotland.

Responsibilities:

As a Sales Consultant you will be responsible for developing business and promoting services in a team to clients in the UK and Europe.  This will involve consultation with clients, identifying additional business opportunities and developing and maintaining long term relationships to new and existing customers.

Qualifications:

The successful candidate for this Sales Consultant role you must be qualified to minimum BSc in a pharmaceutical science related subject or possess equivalent commercial experience.  You must also have a proven track record in business development or sales within aCRO or pharmaceutical organisation. 

How to apply:

For more information or too apply for this  Sales Consultant role please contact Carrie-Ann Bell on 0191 384 8905 or email cbell@ckscience.co.uk.  Please quote reference DH22840 in all correspondence.

                                                     Click here to apply here now!

GSK plans to build UK factory and create 1,000 jobs

Monday, October 31st, 2011

As reported in This is Money.co.uk, the pharmaceutical company GlaxoSmithKline (GSK) is planning on building it’s first new UK factory in 30 years. This will create 1,000 jobs.

As Andrew Witty, CEO of GSK explains, the plan comes are a result of tax breaks on innovation introduced by Chancellor George Osbourne,  ‘Because of changes in the UK tax regime, it will be our intention to bring more activity to Britain and take advantage of the situation here and increase our contribution to Britain. If it [corporation tax] is going to come down over the next few years, it will attract us to pay more tax here.’

The global pharma are considering Cumbria, County Durham and two locations in Scotland for their new factory. A decision is expected to be made in May.

Looking for a new position in the Pharmaceutical Industry? Click here to search our current pharmaceutical jobs now.

North West Biomedical Firms Receive Investment

Thursday, August 4th, 2011

Two biomedical companies, Alchemy Healthcare and Future Medical Technologies, are to each receive £50,000 from the North West Fund for Biomedical, reports pharmatimes.com.

The North West Fund is run by venture capital firm SPARK Impact and supplies debt and equity funding to small and medium sized businesses in the North West of England. Alchemy Healthcare has developed a nasal device for administering treatments in order to avoid injections. The investment they will receive will be used to “complete various elements of tooling and a modest clinical trial,” said Ian Harrison, the firm’s founder. They also hope to receive the results soon and receive further investment.

Future Medical Technologies has developed a polymer to mimic cartilage that is used to help arthritis, improving patient care. The investment will be used to speed development of the product and gain further regulatory approval. Dr Yousef Taktak has called the investment a “great opportunity.”

Looking for a job in the science industry? Start by clicking here, now

Cell Biologist – Cambridge

Thursday, July 28th, 2011

Julie Marshall  is currently recruiting for a Cell Biologist to join a Biopharma Unit in Cambridge on a temporary basis.

Responsibilities:

As a Cell Biologist you will assist with characterisation of the binding properties and biological activity of domain antibodies and recombinant proteins to support early stage drug discovery programmes.

The ideal candidate:

The ideal candidate for this Cell Biologist role will have the following skills:

  • Essential for this role is your practical experience in cell culture, assay development and optimisation of fluorescence based techniques such as Flow Cytometry, confocal microscopy and FRET.
  • Ability to implement and run siRNA knockdown protocols is essential.
  • You should be highly motivated and have a proven ability to handle multiple projects working both within a team and independently.
  • Your experience of biological assay techniques will be complemented with a desire to develop, trouble shoot and validate protocols. 

Qualifications:

For this Cell Biologist role you must have a life science degree, PhD (or equivalent) and research experience in the field of cell biology and an understanding of molecular biology would be advantageous.  This is a temporary position until December 2011.

How to apply:

For more information for or to apply for this Cell Biologist role please contact Julie Marshall on jmarshall@ckscience.co.uk.  Please quote reference ST22426 in all correspondence.

                                                               Click here to apply now!

Benfits Merger Worry For Pharma Companies

Tuesday, July 26th, 2011

Two pharmacy benefits companies are set to merge in a multi-billion dollar deal, reports fiercepharma.com.

Pharmaceutical companies are beginning to worry that due to the proposed $29 billion deal that will see Express Scripts buy Medco Health Solutions, drug prices could decrease, affecting the pharamceutical compnies profits. Most who have commented on the deal, including Eli Lilly’s CFO Dernica Rice, have played down the impact the buy-out will have, with Rice saying Lilly could maintain its negotiation power through their products advantage over the generic drugs on the market.

However, Michael Luby, of BioPharma Alliance, believes the merger will mean the combined company would have “extraordinary purchasing power… [and] leverage [over] pharmaceutical companies.” Price cuts in Europe; particularly Germany and Spain, have been causing pharmaceutical companies problems, and having staved off effort from the US government over pricing, the big companies are now going to have to attempt to stop the private sector submitting the pharmaceutical sector to the same pricing measures.

Looking for a job in the science industry? Start by clicking here, now

Pfizer Separate Divisions to Allow Growth

Friday, July 8th, 2011

Pharmaceutical company Pfizer’s decision to separate certain divisions could lead to a larger break up in order for further growth, including in employment, reports forbes.com.

The splitting of the animal health and baby formula businesses from the main company is the beginning of a process to unlock value within the company. Two other sectors will be kept in order to raise their value to $46 billion combined, though investors had hoped the company would split into five distinct divisions.

The two that have broken off were the obvious choices; the animal health business is worth nearly $4 billion so can stand on its own, and the nutrition side is the one that investors were most eager to see separate.

Though some investors may be disappointed that Pfizer hasn’t split all its divisions at once, it means that sectors that could not currently compete on their own have time to grow to the point where they can be world leaders in their own right, potentially creating a large number of jobs worldwide.

Looking for a job in science? Start by clicking here, now

TryggPharma Re-opens Teeside Pharma Plant

Thursday, July 7th, 2011

TryggPharma of Norway is set to re-open a former Lundbeck Pharmaceuticals site in Seal Sands, creating 25 new pharmaceutical jobs, reports peterleemail.com.

A £14 million deal has been agreed in which Lundbeck will sell their site, which they closed during the recession. TryggPharma’s vice president of engineering Peter Harper has said the company is “very impressed with the facility [as it has] easy to access from Norway, Europe and our customers around the world”.

The facility is expected to employ 25 people within 12 months and the company has said there is a “commitment to invest and expand into the future of Teeside”. The North East Process Industry Cluster chief executive Stan Higgins has said the re-opening of the site is “great news for Teeside and for the pharmaceutical sector in particular”.

Looking for a job in science? Start by clicking here now

Pfizer Retains Pharma Jobs in Kent

Tuesday, July 5th, 2011

Drugs giant Pfizer has announced it will retain 350 jobs in a pharmaceutical sciences operation, whilst still going forward with the planned reduction of the research and development facility in Sandwich, Kent, the Independent reports.

Pfizer hopes the retention of a presence on the site will encourage investors and support the current development of products, despite the loss of around 2,000 jobs at the site. The company will also be working in tandem with Kent County Council in order to encourage other businesses and investors to settle on the site.

Pfizer has a long relationship with Sandwich stretching over 50 years, with a variety of medical discoveries being made there, including that of Viagra.

Looking for a job in science? Start looking here

Search for a job

Advanced search

20 years Download the CK Science iPhone App

Subscribe to our newsletter

Preview
Powered by FeedBlitz